Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Plan Ahead: Clinical Tips for Managing Reproductive Health in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  Issue: November 2024  |  September 24, 2024

For a young woman with active seropositive, erosive rheumatoid arthritis who is planning to have children, it’s essential to ask when the pregnancy is desired. When Dr. Soh asks patients this question, she is frequently surprised to learn that the timeframe the patient has in mind is over the subsequent two to three years. This may provide a window of opportunity to quickly escalate therapy, treating the disease aggressively and then allowing for a period of drug washout prior to an intended pregnancy after the disease is stable.

In a second case, a young woman with previously well-controlled axial spondyloarthritis on NSAID therapy alone became wheelchair-bound due to acute worsening of back pain in her first trimester of pregnancy. Treatments beyond acetaminophen—or paracetamol, which is used in New Zealand—ought to be strongly considered. These treatments can and should include tumor necrosis factor (TNF) alpha (α) inhibitors and secukinumab.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biologic Therapy

Dr. Soh expanded on the topic of biologic therapy in pregnancy and its possible effects on the fetus. She explained that fetal immunoglobulin G1 (IgG1) levels reach 50% that of maternal levels between 28 and 32 weeks of gestation. These levels increase exponentially thereafter because there is maximal placental immunoglobulin transfer from mother to baby in the final four weeks before delivery.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Cord blood levels of biologic medications have been studied and depend on several factors:

  • The point in gestation when the drug was used (i.e., the later in pregnancy, the higher the level);
  • The structure of the Fc receptor because medications lacking an Fc portion, such as certolizumab, are less efficiently transported across the placenta; and
  • The half-life of the drug because the longer its half-life, the more likely there will be placental transfer.3

One reason to be cautious with biologics during pregnancy is because of the potential for the fetus to develop immunosuppression. Such immunosuppression may have practical implications, including the risk of infection for the fetus in utero or after delivery.

Dr. Soh said that, in newborns with in utero biologic medication exposure, live vaccines should be avoided for the first six to eight months of life. The only potential exceptions are rotavirus vaccination and Bacillus Calmette-Guérin vaccination in newborns not exposed to TNF inhibitors.

Dr. Soh said that one of the most joyous parts of her practice is to help a patient have a healthy & successful pregnancy as they seek to start or grow their family.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)pregnancypregnancy complicationspregnant women

Related Articles

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

    November 16, 2016

    The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

    AndreyCherkasov / Shutterstock.com

    Rheumatic Disease Does Not Preclude Pregnancy

    November 9, 2017

    Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…

    Treat to Target: Rheumatoid Arthritis in Pregnant Patients

    October 1, 2012

    A treat-to-target approach to managing rheumatoid arthritis can work even in pregnant women

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences